Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The other 743 women (median age, 49 years; range, 23-80; 71.5% white) received trastuzumab 6 mg/kg via IV every 3 weeks for 14 cycles. Invasive DFS served as the primary endpoint. OS served as a ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Alteogen will receive an upfront payment of $20 million, with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab ... versions of IV Enhertu, which ...

New Intellectual Property In 2024, additional refinements were made towards finalizing the manufacturing of GP2, the reconstitution of GLSI-100 in the pharmacy, and the injection of GLSI ... and ...

Q4 U.S. sales were negatively impacted by Hurricane Helene which as many of disrupted IV supplies and therefore ... two additional data sets from ADPD, Trastuzumab, the PADOVA data from end ...

That means the biosimilar competitors will be chasing an IV market which represents a relatively ... He said he expects Celltrion's trastuzumab will be up to 50% cheaper than Roche's subcutaneous ...

New Intellectual Property In 2024, additional refinements were made towards finalizing the manufacturing of GP2, the reconstitution of GLSI-100 in the pharmacy, and the injection of GLSI ... and ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

every three weeks or IV trastuzumab monotherapy at a dose 6 mg per kilogram every three weeks for 14 cycles. Randomization was arranged as per clinical stage at presentation, specifically inoperable ...